One approach is to combine CD47-targeted therapies with other immune checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies, to overcome the immune evasion mechanisms employed by tumor cells [12,105]. Here, CD47 is linked to neoplasm.